GPR41 CRISPR Activation Plasmid (h): sc-402190-ACT
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- GPR41 CRISPR Activation Plasmid (h) is a synergistic activation mediator (SAM) transcription activation system designed to specifically upregulate gene expression
- GPR41 CRISPR Activation Plasmid (h) consists of three plasmids at a 1:1:1 mass ratio: a plasmid encoding the deactivated Cas9 (dCas9) nuclease (D10A and N863A) fused to the transactivation domain VP64, and a blasticidin resistance gene; a plasmid encoding the MS2-p65-HSF1 fusion protein, and a hygromycin resistance gene; a plasmid encoding a target-specific 20 nt guide RNA fused to two MS2 RNA aptamers, and a puromycin resistance gene
- The resulting SAM complex binds to a site-specific region approximately 200-250 nt upstream of the transcriptional start site and provides robust recruitment of transcription factors for highly efficient gene activation
- gRNAs encoded by GPR41 CRISPR Activation Plasmid (h) and GPR41 CRISPR Activation Plasmid (h2) target distinct regulatory regions upstream of the FFAR3 transcriptional start site. One or both designs may be available
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
GPR41 CRISPR Activation Plasmid (h) | sc-402190-ACT | 20 µg | $397.00 |
FFAR3 encodes the G protein-coupled receptor GPR41, a cell-surface sensor for short-chain fatty acids such as propionate and butyrate derived from microbial fermentation. Upon ligand engagement, GPR41 primarily couples to Gi/o signaling to reduce cAMP and modulate downstream pathways that influence cellular metabolism, energy homeostasis, and inflammatory tone. FFAR3/GPR41 activity has been linked to regulation of hormone secretion and neuroimmune communication, positioning it at the intersection of gut–microbiome signaling and host physiology. Dysregulated FFAR3 signaling is therefore of interest in studies of metabolic dysfunction and inflammatory disease mechanisms where GPCR-mediated nutrient sensing is perturbed.
GPR41 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous FFAR3 expression without altering the underlying DNA sequence.
GPR41 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the FFAR3 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the FFAR3 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous GPR41 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native FFAR3 locus and enabling the study of GPR41-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of GPR41 pathway restoration in tumor cells with silenced or reduced FFAR3 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.